Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Non-Small-Cell Lung Cancer: Recent Advances in Therapeutic Approaches
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Non-Small-Cell Lung Cancer: Recent Advances in Therapeutic Approaches

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Respiratory Medicine".

Deadline for manuscript submissions: 25 August 2025 | Viewed by 568

Special Issue Editors

Dr. Antonio Mazzella

E-Mail Website
Guest Editor
Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Via Ripamonti, 435, 20141 Milan, Italy
Interests: thoracic surgery; mediastinal diseases; mesothelioma; video-assisted thoracic surgery; cardiovascular surgery; thoracic diseases; malignant pleural effusion; lung diseases; lung cancer; minimally invasive surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Giuseppe Mangiameli

E-Mail Website
Guest Editor
1. Division of Thoracic Surgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy
2. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy
Interests: lung cancer; NSCLC; robotic surgery; screening program; precision medicine; SARS-CoV-2; thoracic surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Pietro Bertoglio

E-Mail Website
Guest Editor
1. Division of Thoracic Surgery, IRCSS Azienda Ospedaliero-Universitaria, Bologna, Italy
2. Alma Mater Studiorum, University of Bologna, Bologna, Italy
Interests: thoracic surgery; VATS; robotic surgery; NSCLC; lung adenocarcinoma; MiRNA; multimodality
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are witnessing extraordinary oncological and medical changes in the management of lung cancer. This change in paradigm is principally due to the significant advancement of technology (both in surgery and oncology), the advent of AI (artificial intelligence), or the development of new, more and more precise, anti-neoplastic drugs.

We aim to publish articles describing recent advances in the treatment of non-small-cell lung cancer, from minimally invasive and robotic surgery for early or locally advanced lung cancer to more complex cases, including post-neoadjuvant (immunotherapy or biological therapy) surgery. In this Special Issue, we would even like to explore bronchoscopic advances with new robotic bronchoscopy (ION) or electromagnetic navigation bronchoscopy and all medically innovative treatments.

In this Special Issue, we invite authors to submit papers on all the recent advances in the therapeutic approaches to NSCLC (non-small-cell lung cancer).

Dr. Antonio Mazzella
Dr. Giuseppe Mangiameli
Dr. Pietro Bertoglio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung diseases
  • lung cancer
  • non-small-cell lung cancer(NSCLC)
  • diagnosis
  • surgery
  • treatment
  • artificial intelligence
  • robotic surgery
  • minimally invasive surgery
  • eletromagnetic navigation
  • ION robotic bronchoscopy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 208 KiB  
Article
The Short-Term Impact of Neoadjuvant Chemotherapy on the Outcome of Patients Undergoing Pneumonectomy for Lung Cancer: Is It Acceptable Nowadays?
by Antonio Mazzella, Sebastiano Maiorca, Giuseppe Nicolosi, Patrick Maisonneuve, Antonio Passaro, Monica Casiraghi, Luca Bertolaccini, Filippo de Marinis and Lorenzo Spaggiari
J. Clin. Med. 2025, 14(7), 2419; https://doi.org/10.3390/jcm14072419 - 1 Apr 2025
Viewed by 389
Abstract
Objective: We aimed at assessing our experience at the European Institute of Oncology in order to evaluate the peri- and immediately post-operative impact of neoadjuvant chemotherapy in patients who underwent pneumonectomy for NSCLC. Materials and methods: We retrospectively reviewed the outcomes and medical [...] Read more.
Objective: We aimed at assessing our experience at the European Institute of Oncology in order to evaluate the peri- and immediately post-operative impact of neoadjuvant chemotherapy in patients who underwent pneumonectomy for NSCLC. Materials and methods: We retrospectively reviewed the outcomes and medical records of patients undergoing pneumonectomy (2010–2024). We compared pre-, peri- and post-operative outcomes of patients treated with induction chemotherapy and subsequent pneumonectomy with patients who underwent surgery directly. Differences in their distribution between study arms were assessed using the chi-square test for categorical variables or the Mantel–Haenszel test for trend for ordinal variables. We tested normality of the distribution of continuous variables using the Shapiro–Wilk test. We used logistic regression to quantify the risk of various outcomes (complications, 30-day and 12-day mortality) in patients who received neoadjuvant chemotherapy. Risks were expressed as odds ratios (ORs) with 95% confidence intervals (CIs adjusted for age (<60, 60–64, 65–69, ≥70 years), sex and comorbidities (cardiovascular, pulmonary or previous cancer). Results: We observed a higher frequency of post-operative respiratory complications in patients who underwent neoadjuvant therapy and pneumonectomy compared to those who only underwent surgery (11.4% vs. 18.5%; p = 0.05). After adjustment for age, sex and comorbidities we observed a significantly higher rate of pulmonary complications (OR 1.95; 95% CI 1.09–3.47; p = 0.02), ARDS (OR 2.88; 95% CI 1.26–6.59; p = 0.02) and 30-day mortality rate (OR 8.19; 95% CI 1.33–50.3; p = 0.02) in pre-treated patients. Conclusions: It is therefore strongly recommended to study and select potentially eligible patients in an extremely meticulous way before starting the neoadjuvant treatment, and to thoroughly re-evaluate the cardiorespiratory status after inductive therapy, before surgery. Full article
(This article belongs to the Special Issue Non-Small-Cell Lung Cancer: Recent Advances in Therapeutic Approaches)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop